The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
John H SaundersChristopher R BowmanAlex M Reece-SmithVincent PangMatthew S DorringtonErrum MumtazIrshad SoomroPhilip KayeSrinivasan MadhusudanSimon L ParsonsPublished in: Journal of surgical oncology (2017)
These results suggest the benefit of the adjuvant portion of chemotherapy is limited to those who demonstrate a histopathological response to neoadjuvant chemotherapy. The administration of the adjuvant portion of chemotherapy to patients without a response to neoadjuvant chemotherapy may not provide any survival benefit, while potentially causing increased morbidity.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- early stage
- sentinel lymph node
- end stage renal disease
- ejection fraction
- lymph node
- newly diagnosed
- chronic kidney disease
- minimally invasive
- peritoneal dialysis
- papillary thyroid
- prognostic factors
- coronary artery bypass
- atrial fibrillation
- patient reported outcomes
- squamous cell
- lymph node metastasis
- free survival
- childhood cancer